- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00459381
Pazopanib in Treating Patients With Recurrent Glioblastoma
A Phase II Trial of GW786034 (Pazopanib) in Patients With Recurrent Glioblastoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the therapeutic efficacy of pazopanib hydrochloride, as measured by 6-month progression-free survival (PFS), in patients with recurrent glioblastoma.
II. Determine the safety profile of this drug in these patients.
SECONDARY OBJECTIVES:
I. Determine the efficacy of this drug, as measured by radiographic response, time to progression, and overall survival, in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically for at least 2 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90095
- University of California Los Angeles
-
San Francisco, California, United States, 94115
- University of California San Francisco
-
-
Maryland
-
Bethesda, Maryland, United States, 20814
- National Cancer Institute Neuro-Oncology Branch
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10021
- Memorial Sloan-Kettering Cancer Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15232
- University of Pittsburgh
-
-
Texas
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed glioblastoma multiforme, including gliosarcoma
- Recurrent disease
Must have unequivocal radiographic evidence of tumor progression by MRI, as defined by any of the following:
- 25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) using the same techniques as baseline
- Clear worsening of any evaluable disease
- Appearance of any new lesions or site
- Clear clinical worsening
- Must have failed prior radiotherapy that was completed ≥ 42 days ago
- Patients who received prior therapy that included interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progressive disease, rather than radiation necrosis, based on positron emission tomography (PET) scan, thallium scanning, magnetic resonance spectroscopy, or surgical documentation of disease
Treatment for no more than 2 prior relapses allowed
Relapse is defined as progression following initial therapy (i.e., radiotherapy with or without chemotherapy, if that was used as initial therapy; therefore no more than 3 prior therapies [initial therapy and therapy for 2 relapses] allowed)
- If the patient had a surgical resection for relapsed disease and no anticancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse
- For patients who had prior therapy for a low-grade glioma, the surgical diagnosis of a glioblastoma multiforme will be considered the first relapse
- Karnofsky performance status 60-100%
- Life expectancy > 8 weeks
- WBC ≥ 3,000/mm^3
- Absolute neutrophil count ≥ 1,500/mm^3
- Hemoglobin ≥ 10 g/dL (may be reached by transfusion)
- Platelet count ≥ 100,000/mm^3
- PT/INR/PTT ≤ 1.2 times upper limit of normal (ULN)
- SGOT < 2.5 times ULN
- Bilirubin < 2.5 times ULN
- Creatinine < 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
- Urine protein:creatinine ratio > 1 OR urine protein < 1,000 mg by 24-hour urine collection OR proteinuria < 1+
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective double-barrier contraception during study therapy OR practice abstinence from sexual intercourse for 14 days prior to, during, and for ≥ 21 days after study therapy
Systolic blood pressure (BP) ≤ 140 mm Hg and diastolic BP ≤ 90 mm Hg
- Prior initiation or adjustment of BP medication allowed provided the average of 3 BP readings is ≤ 140/90 mm Hg
- No uncontrolled significant medical illnesses that would preclude study therapy
No other conditions, including any of the following:
- Serious or nonhealing wound, ulcer, or bone fracture
- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- Cerebrovascular accident (CVA) within the past 6 months
- Myocardial infarction, cardiac arrhythmia, admission for unstable angina, cardiac angioplasty, or stenting within the past 84 days
- Venous thrombosis within the past 84 days
New York Heart Association (NYHA) class III or IV heart failure
- Asymptomatic NYHA class II heart failure while on treatment allowed
- No other cancer except for nonmelanoma skin cancer or carcinoma in situ of the cervix unless in complete remission and off of all therapy for that disease for ≥ 3 years
- No disease that would obscure toxicity or dangerously alter drug metabolism
- No history of allergic reactions attributed to compounds of similar chemical or biological composition to pazopanib hydrochloride or other agents
- No QTc prolongation (i.e., QTc interval ≥ 500 msecs) or other significant ECG abnormalities
No condition that impairs the ability to swallow and retain pazopanib hydrochloride, including any of the following:
- Gastrointestinal tract disease resulting in an inability to take oral medication
- Requirement for IV alimentation
- Prior surgical procedures affecting absorption
- Active peptic ulcer disease
- See Disease Characteristics
- Recovered from prior therapy
At least 28 days since prior resection of recurrent or progressive tumor and recovered
- Residual disease after resection of recurrent glioblastoma is not mandated for eligibility into the study
More than 7 days since prior noncytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin)
- Radiosensitizers allowed
- More than 14 days since prior investigational agents
- More than 14 days since prior vincristine
- More than 21 days since prior procarbazine
- More than 28 days since prior cytotoxic therapy
- More than 42 days since prior nitrosoureas
- No prior bevacizumab
- No prior sorafenib tosylate or sunitinib malate
- No prior pazopanib hydrochloride
No concurrent CYP2C9 substrates, including any of the following:
- Anticoagulants (e.g., warfarin [therapeutic doses only])
- Oral hypoglycemics (e.g., glipizide, glyburide, tolbutamide, glimepiride, or nateglinide)
- Ergot derivatives (e.g., dihydroergotamine, ergonovine, ergotamine, or methylergonovine)
- Neuroleptics (e.g., pimozide)
- Erectile dysfunction agents (e.g., sildenafil, tadalafil, or vardenafil)
- Antiarrhythmics (e.g., bepridil, flecainide, lidocaine, mexilitine, amiodarone, quinidine, or propafenone)
- Immune modulators (e.g., cyclosporine, tacrolimus, or sirolimus)
- Miscellaneous drugs (e.g., theophylline, quetiapine, risperidone, tacrine, clozapine, or atomoxetine)
- No concurrent combination antiretroviral therapy for HIV-positive patients
- No other concurrent anticancer therapy (including chemotherapy, radiotherapy, hormonal treatment, or immunotherapy) or investigational drugs
No concurrent enzyme-inducing anti-epileptic drugs (EIAEDs)
- Non-EIAEDs allowed
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (pazopanib hydrochloride)
Patients receive oral pazopanib hydrochloride daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Other: laboratory biomarker analysis |
Correlative studies
Given orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6 Months Progression-free Survival
Time Frame: 6 months
|
Calculated from study registration till 6month time point.
Progression defined by Macdonald criteria Progression imaging features: 25% of more increase in enhancing lesions; any new lesions clinical features: clinical deterioration
|
6 months
|
Number of Participants Discontinuing Treatment Due to Toxicity
Time Frame: 2 years
|
Use NCI Common toxicity Criteria Adverse Event Version 3.0 to grade toxicities.
Any patient who received at least one dose of pazopanib was evaluable for toxicity.
Calculated the number of participants who had an event that was related to pazopanib that caused the patient to stop treatment due to this event.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Most Common Toxicities Experienced After at Least One Dose of Pazopanib
Time Frame: Up to 2 years
|
NCI Common Toxicity Criteria (CTCAE) version 3.0.
All patients that received at least one dose of pazopanib were evaluable.
All events recorded that were related to drug were calculated per patient.
|
Up to 2 years
|
Overall Radiographic Response (ORR) Rate
Time Frame: 2 years
|
The Macdonald criteria, roughly similarly to other systems, divides response into 4 types of response based on imaging (MRI) and clinical features 1: complete response; 2: partial response; 3:stable disease; 4:progression Complete response imaging features: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks; no new lesions clinical features; no corticosteroids; clinically stable or improved Partial response imaging features: 50% or more decrease of all measurable enhancing lesions sustained for at least 4 weeks: no new lesions clinical features: stable or reduced corticosteroids; clinically stable or improved Stable disease imaging features: does not qualify for complete response, partial response or progression clinical features: clinically stable Progression imaging features: 25% of more increase in enhancing lesions; any new lesions clinical features: clinical deterioration |
2 years
|
Best Radiographic Response
Time Frame: 3 years
|
Using the Macdonald criteria, the best MRI image response while the patient was on active treatment. 1: complete response; 2: partial response; 3:stable disease; 4:progression Complete response imaging features: disappearance of all enhancing disease (measurable and non-measurable) sustained for at least 4 weeks; no new lesions clinical features; no corticosteroids; clinically stable or improved Partial response imaging features: 50% or more decrease of all measurable enhancing lesions sustained for at least 4 weeks: no new lesions clinical features: stable or reduced corticosteroids; clinically stable or improved Stable disease imaging features: does not qualify for complete response, partial response or progression clinical features: clinically stable Progression imaging features: 25% of more increase in enhancing lesions; any new lesions clinical features: clinical deterioration |
3 years
|
Overall Survival
Time Frame: From date of registration to date of death due to any cause, assessed up to 2 years
|
calculated from study registration until date of death or patient censored at the last date known alive
|
From date of registration to date of death due to any cause, assessed up to 2 years
|
Time to Progression or Progression Free Survival
Time Frame: 1 year
|
PFS for patients who died on treatment or within 30 days of the end of treatment w/out progression date, was date of death. All other pts without documented progression were censored at the date of last follow-up prior to start new treatment. All 35 patients were included in an intent to treat analysis for PFS and OS. 3 pts censored for PFS, all less than 2 wks after study registration. |
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Howard Fine, MD, North American Brain Tumor Consortium
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2012-02710
- U01CA062399 (U.S. NIH Grant/Contract)
- NABTC-0602
- CDR0000538083 (Registry Identifier: PDQ (Physician Data Query))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Giant Cell Glioblastoma
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Pilocytic Astrocytoma | Adult Pineal Gland Astrocytoma | Recurrent Adult Brain Tumor | Adult Subependymal Giant...United States
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Giant Cell Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingAdult Anaplastic Astrocytoma | Adult Anaplastic Ependymoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Ependymoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Myxopapillary Ependymoma | Adult Oligodendroglioma | Adult Pilocytic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
NRG OncologyNational Cancer Institute (NCI); Radiation Therapy Oncology GroupActive, not recruitingAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States, Canada
Clinical Trials on laboratory biomarker analysis
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
National Cancer Institute (NCI)Recruiting
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingLynch Syndrome | Recurrent Uterine Corpus Carcinoma | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)Not yet recruitingRecurrent Uterine Corpus Carcinoma | Stage III Uterine Corpus Cancer | Stage IV Uterine Corpus CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)RecruitingStage IIIA Ovarian Cancer | Stage IIIB Ovarian Cancer | Stage IIIC Ovarian Cancer | Stage IV Ovarian CancerUnited States
-
National Cancer Institute (NCI)Active, not recruitingMalignant NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingLung Cancer | Radiation Toxicity | Adult Brain TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Askin TumorUnited States, Canada, Puerto Rico, Australia, New Zealand, Switzerland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed